Alerts in the last 24 hours

No Personalised Alerts!

To see personalised alerts you need to be logged in.

Log In

AstraZeneca Add to portfolio

NYA:AZN, Sep 30, 03:21 UTC

Latest NYA:AZN News

Filter your feed

Apply Filter

Yesterday


News

Astrazeneca News Headlines. AZN Share News. Financial News Articles for Astrazeneca Plc Ord Shs $0.25 updated throughout the day.

BREXIT AZN +1 more BREXIT AZN AZN

Hand sanitizer and surface cleaner company Byotrol had a strong 2020 and are confident about 2021 Watch Now. (Adds details on collaboration, background)BENGALURU, Sept 29 (Reuters) - Serum Institute of India will make up to 200 million COVID-19 vaccine doses for poorer countries, including India, next year, as the Bill & Melinda Gates Foundation and GAVI... TIMELINE-How the global coronavirus pandemic unfolded. GENEVA/LONDON, Sept 28 (Reuters) - The official global toll of deaths from COVID-19 probably underestimates the true total - suggesting it could be over a million already, a World Health Organization official said on Monday. MILAN, Sept 28 (Reuters) - Italian biotech firm IRBM, which is cooperating with British drugmaker AstraZeneca in developing a COVID-19 vaccine, could be listed on the stock exchange, its chief executive said on Monday.

Read Full Details

Story Sources

lse.co.uk lse.co.uk
Topics:
  • Business
  • Financial
  • Health

Monday, September 28


News

Astrazeneca (AZN) Stock Sinks As Market Gains: What You Should Know

AZN AZN

Investors will be hoping for strength from AZN as it approaches its next earnings release. Meanwhile, our latest consensus estimate is calling for revenue of $6.66 billion, up 3.92% from the prior-year quarter. For the full year, our Zacks Consensus Estimates are projecting earnings of $2.03 per share and revenue of $26.26 billion, which would represent changes of +16% and +7.69%, respectively, from the prior year. Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Its industry sports an average Forward P/E of 14.57, so we one might conclude that AZN is trading at a premium comparatively.

Read Full Details

Topics:
  • Business
  • Financial
News

Astrazeneca News Headlines. AZN Share News. Financial News Articles for Astrazeneca Plc Ord Shs $0.25 updated throughout the day.

AZN AZN

Hand sanitizer and surface cleaner company Byotrol had a strong 2020 and are confident about 2021 Watch Now. "Why not? ", Piero Di Lorenzo told Italian newspaper IlRiformista, answering a question on whether the stock exchangecould be in the company's future. "Many big companies would like to enter our capital. We arereceiving interest from all over the world and I don't rule outany option," he said, adding however that such a decision wasnot currently a priority, given the focus on the vaccine. The group has already produced tens of thousands of vaccinedoses for the trial stage and has the potential to produce up to10 million doses a year. However, it does not have a production contract withAstraZeneca yet "but it is likely to, in the future", Di Lorenzosaid. MILAN, Sept 28 (Reuters) - Italian biotech firm IRBM, which is cooperating with British drugmaker AstraZeneca in developing a COVID-19 vaccine, could be listed on the stock exchange, its chief executive said on Monday.

Read Full Details

Topics:
  • Business
  • Financial

Friday, September 25


News

Canada has signed deal for AstraZeneca vaccine candidate - PM

AZN AZN

Canada has signed deal for AstraZeneca vaccine candidate - PM. {{monthName}} {{day}}, {{year}}, {{hour12}}:{{minuteTwoDigit}} {{dayPeriod}}. OTTAWA, Sept 25 (Reuters) - Canada has signed a deal with Cambridge-based AstraZeneca to buy up to 20 million doses of its COVID-19 vaccine candidate, Prime Minister Justin Trudeau told reporters on Friday. The medication is among the leading candidates in the global race for a vaccine, now in late-stage trials in Britain, South Africa and elsewhere. (Reporting by David Ljunggren) View more on Yahoo Finance.

Read Full Details

Topics:
  • Health
  • Technology
  • Business
  • Financial
News

AstraZeneca gets partial immunity in low-cost EU vaccine deal

AZN AZN

EU states to pay part of legal bill in case of problems. AstraZeneca got partial waiver for low vaccine price. Filling and packaging tests for the large-scale production and supply of the University of Oxford's COVID-19 vaccine candidate, AZD1222, taking place at a site southeast of Rome, Italy, on September 11, 2020. European governments will pay claims above an agreed limit against AstraZeneca over side-effects from its potential COVID-19 vaccine, under different terms to a deal struck with Sanofi, an EU official toldReuters. The deals reflect different strategies by two of the world's top drugmakers for protecting themselves as a debate rages about liabilities for vaccines aimed at ending the pandemic. AstraZeneca has secured the European Union's backing in a confidential agreement which reflects the lower price sought by the British drugmaker, the official said.

Read Full Details

Topics:
  • Business
  • Health
  • Financial
News

Exclusive: AstraZeneca gets partial immunity in low-cost EU vaccine deal

AZN AZN

BRUSSELS (Reuters) - European governments will pay claims above an agreed limit against AstraZeneca over side-effects from its potential COVID-19 vaccine, under different terms to a deal struck with Sanofi, an EU official told Reuters. The deals reflect different strategies by two of the world's top drugmakers for protecting themselves as a debate rages about liabilities for vaccines aimed at ending the pandemic. AstraZeneca <AZN.L> has secured the European Union's backing in a confidential agreement which reflects the lower price sought by the British drugmaker, the official said. The deal with AstraZeneca, which shifts some of the risks involved in the roll-out of a vaccine to taxpayers, was struck in August and its liability clauses have not previously been reported. Under the AstraZeneca deal, EU countries have agreed to pay 2.5 euros ($2.92) per dose, while Sanofi has negotiated a price at around 10 euros, the official said. As part of the supply deals, the only two sealed so far by Brussels, the EU has also made a non-refundable downpayment of 336 million euros to AstraZeneca to secure 400 million doses, proportionately lower than the 324 million euros it paid to Sanofi to secure 300 million doses.

Read Full Details

Topics:
  • Business
  • Health
  • Financial
  • Politics
  • US
News

Exclusive: AstraZeneca gets partial immunity in low-cost EU vaccine deal

AZN AZN

BRUSSELS (Reuters) - European governments will pay claims above an agreed limit against AstraZeneca over side-effects from its potential COVID-19 vaccine, under different terms to a deal struck with Sanofi, an EU official told Reuters. The deals reflect different strategies by two of the world's top drugmakers for protecting themselves as a debate rages about liabilities for vaccines aimed at ending the pandemic. AstraZeneca <AZN.L> has secured the European Union's backing in a confidential agreement which reflects the lower price sought by the British drugmaker, the official said. The deal with AstraZeneca, which shifts some of the risks involved in the roll-out of a vaccine to taxpayers, was struck in August and its liability clauses have not previously been reported. Under the AstraZeneca deal, EU countries have agreed to pay 2.5 euros ($2.92) per dose, while Sanofi has negotiated a price at around 10 euros, the official said. As part of the supply deals, the only two sealed so far by Brussels, the EU has also made a non-refundable downpayment of 336 million euros to AstraZeneca to secure 400 million doses, proportionately lower than the 324 million euros it paid to Sanofi to secure 300 million doses.

Read Full Details

Topics:
  • Business
  • Politics
  • Financial
  • US
  • Health

Thursday, September 24


News

'Trust someone': AstraZeneca boss says transparency key for vaccine

AZN AZN

'Trust someone': AstraZeneca boss says transparency key for vaccine. For our free coronavirus pandemic coverage, learn more here. The chief executive of AstraZeneca has said the public must trust that multiple regulators will review the safety of COVID-19 vaccines, confirming the company is still waiting for the US regulator to review safety data after its vaccine trial was paused. Pascal Soriot told the World Economic Forum's Sustainable Development Impact Summit on Thursday the global biotechnology firm was considering how much transparency it could provide about its vaccine trials, after its phase 3 study was put on hold earlier this month because of an adverse reaction in a participant. "We are looking at how much transparency we can provide considering we are in a very special set of circumstances," he said. AstraZeneca was working with other vaccine makers to discuss how open they could be about their studies without compromising the data they were collecting, Mr Soriot said.

Read Full Details

Topics:
  • Business
  • Health
  • Technology
  • Financial
News

UK shares drop as job support scaled back; AstraZeneca weighs

AZN AZN

U.S. UK shares drop as job support scaled back; AstraZeneca weighs. (Reuters) - London shares dropped on Thursday, hitting session lows after Britain scaled-back job support for workers hit by the resurgent coronavirus pandemic, while AstraZeneca slid as U.S. trials for its COVID-19 vaccine remained on hold. After two days of gains driven by new restrictions to curb a resurgence in COVID-19 cases being less severe than expected, the blue-chip FTSE 100 index .FTSE fell 1.3%, while the mid-caps index .FTMC closed down 1.1%. British finance minister Rishi Sunak unveiled plans to extend loan repayments for businesses and delay ending a tax cut for the hospitality sector. But under a new programme to replace the job retention scheme, which ends next month, government support will only be available to workers whose employers keep them on at least a third of their normal hours, Sunak said. While the measures will go some way to cushioning the blow to economic recovery and limiting the long-term hit to unemployment, it won't eliminate the hit entirely, said Ruth Gregory, senior UK economist with Capital Economics, adding this could see GDP stagnate in the last three months of the year.

Read Full Details

Topics:
  • Business
  • Financial
News

AstraZeneca still waiting for FDA go-ahead to resume U.S. trial

AZN AZN

FRANKFURT (Reuters) - AstraZeneca <AZN.L> is still waiting for the U.S. drug regulator to approve the restart of the clinical trial of its potential COVID-19 vaccine in the United States almost three weeks after it was paused due to safety concerns. The U.S. trial of AstraZeneca's COVID-19 vaccine candidate, initially developed by the University of Oxford, remains on hold while regulators investigate an illness in one of the participants, even after a British study and other programmes outside of the United States have resumed. "We are the sponsor of the U.S. study. We then provided all this information to the FDA (U.S. Food and Drug Administration) and we are waiting to hear their decision," Soriot told a virtual World Economic Forum discussion. A document posted online by Oxford university last week stated the illness in a British participant that triggered the pause on Sept. 6 may not have been associated with the vaccine. Asked why the company had not disclosed details about the nature of the illness, Soriot said clinical trial regulators and independent supervisors were guarding participants' privacy.

Read Full Details

Topics:
  • Health
  • Technology
  • Business
  • Financial